For research use only. PeptaBase is for informational and laboratory research reference only. No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
PeptaBase
✓500+ PubMed Citations✓Free To Use✓No Account Required
Back to Database
Metabolic

Semaglutide Protocol

Dosing & Research

Last Updated: September 4, 2026

Chemical Identity
Molecular Formula
C187H291N45O59
Molecular Weight
4113.64 g/mol
CAS Number
910463-68-2

Weight-loss and diabetes research, Appetite regulation, Cardiometabolic outcomes, GLP-1 pharmacology

Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
Approximately 7 Days
Administration
Subcutaneous
Frequency
Once Or Twice Weekly, Same Day(s) Each Week

How It Works

  • Weight-loss and diabetes research
  • Appetite regulation
  • Cardiometabolic outcomes
  • GLP-1 pharmacology

Dosing Structure

Dose
0.25–2.0 mg weekly
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
Notes
1x Weekly titration: Week 1-4: 0.25mg | Week 5-8: 0.5mg | Week 9-12: 1mg | Week 13-16: 1.7mg | Week 17+: 2.4mg. 2x Weekly titration: Week 1-4: 0.125mg | Week 5-8: 0.25mg | Week 9-12: 0.5mg | Week 13-16: 0.85mg | Week 17+: 1.2mg. No need to increase dose if experiencing benefits at a lower dose. Inject: Abdomen, thigh, or upper arm (rotate weekly). Any time of day, with or without food. Typically follows a weekly titration schedule.

Example Protocols

Dose: 0.25–2.0 mg weekly
Frequency: Once Or Twice Weekly, Same Day(s) Each Week
Duration: 8-48 weeks
Off Period: Not listed
Calculate dosing →

Find Research Grade Semaglutide

Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.

Vendor One Research Labs

COA Verified

Third-party COA-verified research peptides with published batch testing.

Source Coming Soon

Vendor Two Sciences

Purity Tested

US-based research compound supplier with independent purity testing.

Source Coming Soon

Vendor Three Peptide Co.

Bulk research peptide sourcing with batch-level documentation.

Source Coming Soon
View all recommended vendors →

Protocol Notes

1x Weekly titration
Week 1-4: 0.25mgWeek 5-8: 0.5mgWeek 9-12: 1mgWeek 13-16: 1.7mgWeek 17+: 2.4mg
2x Weekly titration
Week 1-4: 0.125mgWeek 5-8: 0.25mgWeek 9-12: 0.5mgWeek 13-16: 0.85mgWeek 17+: 1.2mg
•
No need to increase dose if experiencing benefits at a lower dose.
•
Inject: Abdomen, thigh, or upper arm (rotate weekly).
•
Any time of day, with or without food.
•
Typically follows a weekly titration schedule.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone released after eating, signaling the brain to reduce appetite and the pancreas to release insulin. It is one of the most clinically studied compounds in metabolic medicine, with approved indications for type 2 diabetes and obesity, and emerging data for cardiovascular protection and kidney disease.

Research Observations - Not Medical Claims
  • ▸STEP 1 trial (NEJM, 2021; PMID: 33567185): 2.4 mg/week subcutaneous semaglutide produced 14.9% mean body weight reduction over 68 weeks vs. 2.4% placebo.
  • ▸SELECT trial (NEJM, 2023): 2.4 mg/week reduced major adverse cardiovascular events (MACE) by 20% in overweight/obese adults without diabetes but with established CVD - first weight-loss drug to show cardiovascular mortality benefit.
  • ▸FLOW trial (NEJM, 2024): 1 mg/week semaglutide reduced progression of kidney disease by 24% and kidney failure risk by 38% in T2D patients with CKD.
  • ▸STEP 4 trial (JAMA, 2021): Participants who switched to placebo after 20 weeks regained most lost weight by week 68, demonstrating drug dependency for effect maintenance.
  • ▸Oral semaglutide (Rybelsus, 14 mg): PIONEER 1 trial showed 0.97% HbA1c reduction - less effective than injectable but meaningful for needle-averse patients.

Evidence Summary

Human Clinical Data AvailableFDA Approved - Ozempic (T2D, 2017); Rybelsus (T2D, 2019); Wegovy (obesity, 2021)
Evidence StrengthStrong
PreliminaryModerateStrong
Curated Citations4
Largest Study (n)1,961
Most Recent Study2024
Species Studied
HumanRatMouse

Commonly Researched With

Tirzepatide
Head-to-head comparison rather than combination; both are GLP-1 class, not co-administered.
Retatrutide
Researchers compare outcomes across GLP-1, dual, and triple agonist classes for metabolic efficacy.
NAD+
NAD+ restoration is studied alongside GLP-1 agonists in metabolic longevity research for potential additive effects on mitochondrial health.

Research & Studies

Loading citations…

Research Feedback

0 approved

For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.

Related Peptides

5 Amino 1 MQ
Metabolic
AICAR
Metabolic
AOD-9604
Metabolic
Cagrilintide
Metabolic